PENG vs. FIC Block for Hip Fracture ED Patients
Launched by ANTONIOS LIKOUREZOS · Oct 20, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of pain relief for patients with hip fractures who come to the emergency department (ED). The researchers want to compare two types of ultrasound-guided nerve blocks: the PENG block and the FIC block. Both blocks help reduce pain without relying heavily on opioids, which can cause harmful side effects, especially in older patients. The goal is to see if the PENG block works just as well as the FIC block in managing pain after a hip fracture.
Patients who might be eligible for this trial are adults over 18 years old with a specific type of hip fracture and a pain score of 5 or higher on a scale of 0 to 10. However, those with serious injuries, certain health issues, or who are pregnant or underage cannot participate. If enrolled, participants will receive a small dose of morphine to help with pain before the nerve block is placed, and their pain levels will be checked before and after the procedure. This study aims to find the best way to manage pain for patients with hip fractures, helping them recover more comfortably.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult Emergency Medicine Patients over 18 years of age
- • Isolated hip fracture, intertrocanteric or more proximal
- • Pain score 5 or greater on a scale of 0 to 10 just prior to nerve block placement
- Exclusion Criteria:
- • Patients with multi-system trauma
- • People who are unable to communicate their level of pain\\
- • Pregnant patients
- • Pediatric Patients (less than 18 years of age)
- • Intoxicated Patients
- • Abnormal Vital Signs (HR\>120bpm, MAP \<65, Pulse Ox \<95%)
- • Patients on long term systemic opioid analgesia
- • Allergy to amide local anesthetics
About Antonios Likourezos
Antonios Likourezos is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical development, he leads innovative trials that explore novel therapies and treatment modalities across various therapeutic areas. His strategic approach emphasizes collaboration with healthcare professionals, regulatory bodies, and research institutions, ensuring rigorous adherence to ethical standards and regulatory compliance. Through a patient-centered focus, Antonios Likourezos aims to facilitate the translation of groundbreaking scientific discoveries into effective clinical applications, ultimately contributing to the enhancement of global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brooklyn, New York, United States
Brooklyn, New York, United States
Patients applied
Trial Officials
Lawrence Haines, MD
Principal Investigator
Maimonides Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials